Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A infectious disease involving the Naegleria fowleri.
Biomarker and diagnostic research for primary amebic meningoencephalitis has been reported in the published literature.
No approved treatments are currently available for primary amebic meningoencephalitis. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for primary amebic meningoencephalitis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for primary amebic meningoencephalitis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
No clinical trials have been registered for primary amebic meningoencephalitis.
120 publications have been identified in PubMed for primary amebic meningoencephalitis. Research spans Basic Science / Preclinical (23%), Case Report / Case Series (21%), and Epidemiology / Natural History (21%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 28 | 23% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 11:11 AM UTC
Genetic and Rare Diseases Info Center
Designated
Exclusivity End |
|---|
Designation Status |
|---|
corifungin | corifungin | Ctr for Discovery & Innovation in Parasitic Diseas | 2011 | — | Designated |
Gene therapy approaches for primary amebic meningoencephalitis have been reported in the published literature.
View trials for primary amebic meningoencephalitis
Patient case studies
25 |
21% |
Disease patterns and progression | 25 | 21% |
New treatment approaches | 18 | 15% |
Research summaries | 17 | 14% |
Testing and diagnosis research | 6 | 5% |
Other research | 1 | 1% |
Ashique S (2026). [PMID: 41864595](https://pubmed.ncbi.nlm.nih.gov/41864595/). *Travel Med Infect Dis*. [Epidemiology / Natural History]
Sankar P (2026). [PMID: 41873284](https://pubmed.ncbi.nlm.nih.gov/41873284/). *Cureus*. [Case Report / Case Series]
Miyata H (2026). [PMID: 42156061](https://pubmed.ncbi.nlm.nih.gov/42156061/). *Brain Nerve*. [Review / Meta-Analysis]
Apparasamy D (2026). [PMID: 41970609](https://pubmed.ncbi.nlm.nih.gov/41970609/). *Parasite Epidemiol Control*. [Gene Therapy / Novel Therapeutics]
Sarantopoulos A (2026). [PMID: 42042314](https://pubmed.ncbi.nlm.nih.gov/42042314/). *Infect Dis Rep*. [Review / Meta-Analysis]
Pandit S (2026). [PMID: 42155550](https://pubmed.ncbi.nlm.nih.gov/42155550/). *Diagn Microbiol Infect Dis*. [Review / Meta-Analysis]
Vijayan V (2026). [PMID: 28613505](https://pubmed.ncbi.nlm.nih.gov/28613505/). *Unknown Journal*. [Review / Meta-Analysis]
Fu L (2026). [PMID: 42038227](https://pubmed.ncbi.nlm.nih.gov/42038227/). *Front Pediatr*. [Case Report / Case Series]
Pervin N (2026). [PMID: 30571068](https://pubmed.ncbi.nlm.nih.gov/30571068/). *Unknown Journal*. [Review / Meta-Analysis]
Wang QL (2026). [PMID: 41868024](https://pubmed.ncbi.nlm.nih.gov/41868024/). *Infect Drug Resist*. [Case Report / Case Series]
AI-curated news mentioning primary amebic meningoencephalitis
Updated Jun 10, 2026
Recent research sheds light on primary amoebic meningoencephalitis, enhancing understanding of this rare disease. The study aims to improve diagnosis and treatment strategies for affected patients.
A recent publication discusses the clinical challenges and strategic solutions for pharmacological interventions in primary amoebic meningoencephalitis. The study highlights the need for improved treatment strategies to combat this rare and often fatal disease.